• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用空间增殖的生物物理指标对新辅助治疗的乳腺癌反应进行动态特征描述。

Dynamic characterization of breast cancer response to neoadjuvant therapy using biophysical metrics of spatial proliferation.

机构信息

Department of Biomedical Engineering, Wake Forest School of Medicine, 575 N. Patterson Ave., Suite 530, Winston-Salem, NC, 27101, USA.

Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, USA.

出版信息

Sci Rep. 2022 Jul 9;12(1):11718. doi: 10.1038/s41598-022-15801-7.

DOI:10.1038/s41598-022-15801-7
PMID:35810187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9271064/
Abstract

Current tools to assess breast cancer response to neoadjuvant chemotherapy cannot reliably predict disease eradication, which if possible, could allow early cessation of therapy. In this work, we assessed the ability of an image data-driven mathematical modeling approach for dynamic characterization of breast cancer response to neoadjuvant therapy. We retrospectively analyzed patients enrolled in the I-SPY 2 TRIAL at the Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Patients enrolled on the study received four MR imaging examinations during neoadjuvant therapy with acquisitions at baseline (T), 3-weeks/early-treatment (T), 12-weeks/mid-treatment (T), and completion of therapy prior to surgery (T). We use a biophysical mathematical model of tumor growth to generate spatial estimates of tumor proliferation to characterize the dynamics of treatment response. Using histogram summary metrics to quantify estimated tumor proliferation maps, we found strong correlation of mathematical model-estimated tumor proliferation with residual cancer burden, with Pearson correlation coefficients ranging from 0.88 and 0.97 between T and T, representing a significant improvement from conventional assessment methods of change in mean apparent diffusion coefficient and functional tumor volume. This data shows the significant promise of imaging-based biophysical mathematical modeling methods for dynamic characterization of patient-specific response to neoadjuvant therapy with correlation to residual disease outcomes.

摘要

目前用于评估新辅助化疗治疗乳腺癌反应的工具无法可靠地预测疾病的消除,如果可能的话,这将允许早期停止治疗。在这项工作中,我们评估了一种基于图像数据的数学建模方法来动态描述新辅助治疗中乳腺癌反应的能力。我们回顾性分析了在阿特利姆健康维克森林浸信会综合癌症中心的 I-SPY 2 试验中入组的患者。入组该研究的患者在新辅助治疗期间接受了四次磁共振成像检查,分别在基线(T)、治疗 3 周/早期(T)、治疗 12 周/中期(T)和手术前完成治疗(T)时进行采集。我们使用肿瘤生长的生物物理数学模型来生成肿瘤增殖的空间估计值,以描述治疗反应的动力学。使用直方图汇总指标来量化估计的肿瘤增殖图,我们发现数学模型估计的肿瘤增殖与残留癌负荷之间存在很强的相关性,T 和 T 之间的皮尔逊相关系数范围为 0.88 到 0.97,与传统的评估方法相比,平均表观扩散系数和功能肿瘤体积的变化有显著改善。这些数据表明,基于成像的生物物理数学建模方法在动态描述新辅助治疗中患者特异性反应方面具有很大的潜力,与残留疾病结局相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/168485ed8a4e/41598_2022_15801_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/3c2f9c730e24/41598_2022_15801_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/704fcad7e051/41598_2022_15801_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/f0c3fb31bd20/41598_2022_15801_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/9d68c98903f5/41598_2022_15801_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/fc75899f6a98/41598_2022_15801_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/168485ed8a4e/41598_2022_15801_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/3c2f9c730e24/41598_2022_15801_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/704fcad7e051/41598_2022_15801_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/f0c3fb31bd20/41598_2022_15801_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/9d68c98903f5/41598_2022_15801_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/fc75899f6a98/41598_2022_15801_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9a/9271064/168485ed8a4e/41598_2022_15801_Fig6_HTML.jpg

相似文献

1
Dynamic characterization of breast cancer response to neoadjuvant therapy using biophysical metrics of spatial proliferation.利用空间增殖的生物物理指标对新辅助治疗的乳腺癌反应进行动态特征描述。
Sci Rep. 2022 Jul 9;12(1):11718. doi: 10.1038/s41598-022-15801-7.
2
Characterizing breast cancer response to neoadjuvant therapy based on biophysical modeling and multiparametric magnetic resonance imaging data.基于生物物理模型和多参数磁共振成像数据对乳腺癌新辅助治疗反应进行特征分析。
medRxiv. 2023 Nov 28:2023.11.28.23299112. doi: 10.1101/2023.11.28.23299112.
3
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.MRI 方案依从性对 I-SPY 2 新辅助乳腺癌试验中预测病理完全缓解的影响。
Tomography. 2020 Jun;6(2):77-85. doi: 10.18383/j.tom.2020.00006.
4
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.扩散加权 MRI 在 I-SPY2 试验中的附加价值。
J Magn Reson Imaging. 2019 Dec;50(6):1742-1753. doi: 10.1002/jmri.26770. Epub 2019 Apr 26.
5
Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.扩散张量成像对新辅助化疗乳腺癌反应的定量评估:初步结果。
J Magn Reson Imaging. 2018 Apr;47(4):1080-1090. doi: 10.1002/jmri.25855. Epub 2017 Sep 13.
6
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.局部晚期乳腺癌:MR 成像预测新辅助化疗反应——来自 ACRIN 6657/I-SPY 试验的结果。
Radiology. 2012 Jun;263(3):663-72. doi: 10.1148/radiol.12110748.
7
Efficacy of shear-wave elastography versus dynamic optical breast imaging for predicting the pathological response to neoadjuvant chemotherapy in breast cancer.剪切波弹性成像与动态光学乳腺成像预测乳腺癌新辅助化疗病理反应的效能比较。
Eur J Radiol. 2020 Aug;129:109098. doi: 10.1016/j.ejrad.2020.109098. Epub 2020 Jun 1.
8
Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.弥散加权成像在新辅助化疗后评估乳腺癌残留中的作用:作为对比增强乳腺 MRI 的辅助手段。
Eur J Radiol. 2014 Feb;83(2):283-8. doi: 10.1016/j.ejrad.2013.10.023. Epub 2013 Nov 20.
9
Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.基于 3.0T MRI 的纹理分析对乳腺癌新辅助化疗反应的相关性研究。
Radiology. 2020 Jan;294(1):31-41. doi: 10.1148/radiol.2019182718. Epub 2019 Nov 26.
10
Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.使用扩散加权成像和动态对比增强磁共振成像评估乳腺癌新辅助化疗的疗效。
Neoplasma. 2017;64(3):430-436. doi: 10.4149/neo_2017_314.

引用本文的文献

1
Validating the predictions of mathematical models describing tumor growth and treatment response.验证描述肿瘤生长和治疗反应的数学模型的预测结果。
ArXiv. 2025 Feb 26:arXiv:2502.19333v1.
2
Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.新型计算生物学建模系统可准确预测早期乳腺癌新辅助治疗的反应。
Breast Cancer Res. 2023 May 10;25(1):54. doi: 10.1186/s13058-023-01654-z.

本文引用的文献

1
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.智能真空辅助活检识别新辅助全身治疗后省略乳房和腋窝手术的乳腺癌患者的病理完全缓解(ypT0 和 ypN0)。
J Clin Oncol. 2022 Jun 10;40(17):1903-1915. doi: 10.1200/JCO.21.02439. Epub 2022 Feb 2.
2
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.三阴性乳腺癌的免疫表型和新辅助治疗反应。
Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. doi: 10.1158/1078-0432.CCR-21-0144.
3
I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer.
I-SPY 2:一项旨在改善高危乳腺癌治疗效果的新辅助适应性临床试验。
Curr Breast Cancer Rep. 2019 Dec;11(4):303-310. doi: 10.1007/s12609-019-00334-2. Epub 2019 Nov 20.
4
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.利用多特征磁共振成像预测乳腺癌对新辅助治疗的反应:I-SPY 2试验结果
NPJ Breast Cancer. 2020 Nov 27;6(1):63. doi: 10.1038/s41523-020-00203-7.
5
Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data.通过受定量磁共振成像数据约束的数学模型评估乳腺癌患者的新辅助治疗方案。
Neoplasia. 2020 Dec;22(12):820-830. doi: 10.1016/j.neo.2020.10.011. Epub 2020 Nov 14.
6
Neoadjuvant Radio(chemo)therapy for Breast Cancer: An Old Concept Revisited.乳腺癌的新辅助放(化)疗:重新审视一个旧概念
Breast Care (Basel). 2020 Apr;15(2):112-117. doi: 10.1159/000507041. Epub 2020 Apr 14.
7
Axillary Nodal Evaluation in Breast Cancer: State of the Art.乳腺癌腋窝淋巴结评估:现状。
Radiology. 2020 Jun;295(3):500-515. doi: 10.1148/radiol.2020192534. Epub 2020 Apr 21.
8
Breast MRI: State of the Art.乳腺 MRI:现状。
Radiology. 2019 Sep;292(3):520-536. doi: 10.1148/radiol.2019182947. Epub 2019 Jul 30.
9
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).新辅助化疗后对比增强磁共振成像(CE-MRI)的放射学完全缓解(rCR)可预测无复发生存期,但不能预测病理完全缓解(pCR)。
Breast Cancer Res. 2019 Jan 31;21(1):19. doi: 10.1186/s13058-018-1091-y.
10
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.扩散加权 MRI 表现预测乳腺癌新辅助治疗的病理反应:ACRIN 6698 多中心试验。
Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4.